Dr. Erik Lesley Kimble, MD

Dr. Kimble practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Kimble's NPI, 1750708897, was assigned on March 26, 2014. Dr. Kimble holds Washington license MD61089948.

Dr. Kimble's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Kimble's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Kimble is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kimble practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kimble's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kimble is licensed in Washington.

CMS data shows 203 Medicare services from Dr. Kimble across 3 procedure codes in 2024, for 42 Medicare patients. Medicare paid $19,269 for them.

CMS counts 42 Medicare patients who saw Dr. Kimble in 2024. The largest group is 65 to 74, with 30 patients. 74% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kimble's median patient age at 66, with 35% women.

In 2021, Dr. Kimble wrote 15 Medicare Part D claims. They cover 1 drug, with $8,091 in total drug cost. In 2020, CMS named 35 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Kimble for performance year 2024, reported through an alternative payment model (APM). Dr. Kimble accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kimble as offering telehealth.

Dmand AI links 21 papers to Dr. Kimble, published from 2015 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and T-Lymphocytes. Dr. Kimble has published most often in Blood Adv. Dr. Kimble's most frequent co-authors are Cameron John Turtle, MBBS, PhD, David G. Maloney and Ryan D. Cassaday, MD.

CMS Open Payments shows 12 general payments to Dr. Kimble from 5 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. ADC Therapeutics America, Inc. paid the most, $528.